IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer.
Jian YangDe-Jun LiuJia-Hao ZhengRui-Zhe HeDa-Peng XuMin-Wei YangHong-Fei YaoXue-Liang FuJian-Yu YangYan-Miao HuoLing-Ye TaoRong HuaYong-Wei SunXian-Ming KongShu-Heng JiangWei LiuPublished in: Cellular oncology (Dordrecht) (2022)
Our data reveal a role of IRAK2 in PDAC metabolic reprogramming. In addition, we obtained novel insights into how immune-related pathways affect PDAC progression and suggest that targeting IRAK2 may serve as a novel therapeutic approach for PDAC.